Salix Pharmaceuticals Ltd (SLXP) Misses Q2 EPS by 10c

Salix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q2 EPS of $1.59, $0.10 worse than the analyst estimate of $1.69. Revenue for the quarter came in at $382 million versus the consensus estimate of $397.06 million.

For earnings history and earnings-related data on Salix Pharmaceuticals Ltd (SLXP) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• First Watch (FWRG) PT Lowered to $15 at DA Davidson, Buy Rating Maintained
• Cuprina to buy seven-clinic Singapore healthcare group for S$4M